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A B S T R A C T   
Background: Immune checkpoint inhibitors (ICIs) are standard of care in advanced non-small cell lung cancer 
(NSCLC), however their status in patients with poor performance status (PS) is poorly defined. We aimed to 
evaluate the efficacy and safety of ICIs in NSCLC patients with PS ≥ 2. 
Methods: We conducted a systematic review and meta-analysis of interventional and observational studies, which 
reported efficacy and safety data on ICIs in PS ≥ 2 comparing to PS ≤ 1 NSCLC patients. Efficacy endpoints 
included: Objective Response Rate (ORR), Disease-Control Rate (DCR), Overall Survival (OS), Progression-Free 
Survival (PFS). Safety endpoint was the incidence of severe (grade≥3) Adverse Events (AE). Random-effects 
model was applied for meta-analysis. Heterogeneity was assessed using I2. The review is registered on PROS-
PERO (CRD42020162668). 
Findings: Sixty-seven studies (n = 26,442 patients) were included. In PS ≥ 2 vs. PS ≤ 1 patients, the pooled odds 
ratios were: for ORR 0.46 (95 %CI: 0.39− 0.54, I2:0 %); for DCR 0.39 (95 %CI: 0.33− 0.48, I2:50 %) and for AEs 
1.12 (95 %CI: 0.84–1.48, I2:39 %). The pooled hazard ratio for PFS was 2.17 (95 %CI: 1.96–2.39, I2:65 %) and for 
OS was 2.76 (95 %CI: 2.43–3.14, I2:76 %). The safety profile was comparable regardless of the PS status. 
Interpretation: Patients with impaired PS status are, on average, twice less likely to achieve a response when 
exposed to ICIs when compared with representative PS ≤ 1 population. For lung cancer patients treated with 
ICIs, the impaired PS is not only prognostic, but also predictive for response, while the safety profile is not 
affected. Prospective randomized studies are indispensable to determine whether poor PS patients derive benefit 
from ICIs.   
1. Introduction 
Immune checkpoint inhibitors (ICIs), encompassing antibodies 
against programmed death receptor (PD-1), PD-1 ligand (PD-L1) and 
cytotoxic-T-lymphocytes antigen 4 (CTLA-4), vastly improved the 
outcome of patients with non-small cell lung cancer (NSCLC) and are 
now standard of care in this population [1]. The superior efficacy of ICIs 
has been documented in several randomized clinical trials (RCTs) 
comparing them with chemotherapy in both first and subsequent lines of 
therapy [2]. 
The Eastern Cooperative Oncology Group Performance Status Score 
(PS) is one of the most powerful prognostic factors available to oncol-
ogists [3]. In the past, stratification between PS ≤ 1 versus PS ≥ 2 pa-
tients was obligatory and provided evidence that PS is not only 
prognostic but also predictive for response and toxicity in NSCLC pop-
ulation treated with chemotherapy [4]. In contrast, patients with poor 
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PS were consistently excluded from registrational ICI trials, which pre-
cludes reliable assessment of the treatment in this population (consti-
tuting about 34–48 % of all patients diagnosed with NSCLC worldwide 
[5]). Despite this shortfall, US Food and Drug Administration together 
with European Medicines Agency have granted approval for ICIs in 
NSCLC regardless of the patient PS status. As a consequence, now and for 
several years previously, ICIs are offered to a significant number of 
NSCLC patients, who are not representative of the population tested in 
RCTs. 
As of now, the results of only five prospective ICI trials (all single- 
arm) that included PS ≥ 2 patients have been published [6–10]. How-
ever, except for the recently published PePS2 study [9], these trials 
primarily included PS ≤ 1 patients with a minor additional subsets 
termed “special populations”, i.e. elderly and patients with comorbid-
ities preventing any specific conclusions for PS ≥ 2 patients. The activity 
and safety of ICIs (predominantly nivolumab and pembrolizumab) was 
investigated in several national expanded access programs (EAPs) and a 
growing number of retrospective reports. These “real-world” reports are 
the best currently available evidence to address the important clinical 
evidence gaps for the PS ≥ 2 population. 
We therefore performed a systematic review and meta-analysis of 
randomized clinical trials, observational studies (retrospective and 
prospective), reports from EAPs and compassionate use programs to 
assess the effectiveness and safety of immunotherapy in NSCLC patients 
with PS score of 2 or more with reference to PS 0-1 population. 
2. Methods 
This systematic review with meta-analysis was conducted in accor-
dance with Centre for Reviews and Dissemination (CRD) guidance for 
undertaking reviews in health care and reported according to PRISMA 
guidelines (Appendix A) [11,12]. A protocol was prepared prior to the 
study and prospectively registered at the PROSPERO database (number 
CRD42020162668, Appendix B). Each step of the study was conducted 
by two independent researchers with disputes resolved by discussion. 
We declare that all results are reported and discussed in the paper. 
2.1. Search strategy 
Electronic searches were conducted from origin to 22nd of May 2020 
in OVID MEDLINE®, EMBASE, Cochrane Database of Systematic Re-
views (CDSR), American Society of Clinical Oncology (ASCO) meeting 
abstracts’ database, International Association for the Study of Lung 
Cancer (IASLC) meeting (World Conference on Lung Cancer – WCLC) 
abstracts’ database, EORTC (European Organization for Research and 
Treatment of Cancer) website, European Society for Medical Oncology 
(ESMO) website, American Association for Cancer Research (AACR) 
website, European Cancer Organization (ECCO) website and pubmed. 
com. The searches were rerun before the final analysis of data as of 17th 
July 2020. Searches were supplemented by reviewing the reference lists 
of the publications, previous meta-analyses, and guidelines. The main 
search terms encompassed: non-small cell lung cancer (NSCLC), 
immunotherapy (ICI), anti-PDL1, anti-PD1, anti-CTLA4, pem-
brolizumab, nivolumab, atezolizumab, durvalumab, urelumab, ipili-
mumab, tremelimumab, efficacy, effectiveness, toxicity, safety. The full 
search strategy is available in Appendix C. No language restrictions were 
applied to the search. 
2.2. Assessing for eligibility 
The inclusion criteria for articles were as follows: Population crite-
rion - patients with locally advanced or metastatic/ advanced non-small 
cell lung cancer (as defined in the National Comprehensive Cancer 
Network guidelines); Intervention criterion - immune checkpoint in-
hibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, ure-
lumab, ipilimumab, tremelimumab and any other ICI registered for 
treatment of NSCLC) in >10 patients with PS ≥ 2; Comparator criterion 
– (a) ICIs in patients with PS ≤ 1 or (b) any other active treatments, 
placebo or best supportive care in patients with PS ≥ 2; Outcomes cri-
terion – Effectiveness: Objective Response Rate (ORR), Disease-Control 
Rate (DCR), Overall Survival (OS), Progression-Free Survival (PFS) 
and Safety: incidence of severe (grade≥3) Adverse Events (AE); Study 
design - randomised controlled trial (RCT), non-randomised registered 
clinical trials, retrospective and prospective cohort, cross-sectional, 
case-control, case series studies. 
Articles retrieved from the electronic searches were firstly screened 
for eligibility using their titles and abstracts. Full-text papers of poten-
tially relevant trials were obtained and examined by assessing their 
population, intervention, comparison, outcome measurements and 
study design (PICOS) characteristics. The process of the selection of 
studies is reported in PRISMA flowchart (Fig. 1). 
2.3. Quality assessment 
For quality assessment, dependent on study design, two tools 
recognized by Cochrane Handbook for Systematic Reviews of In-
terventions were selected: i) revised Cochrane risk-of-bias tool for ran-
domized trials (RoB 2) for randomised clinical trials [13]; ii) 
Newcastle-Ottawa Scale for cohort and registry studies [14,15]. All 
full-text article studies were assessed for bias following the checklist 
respective to the tool applied. Detailed evaluation for each study was 
tabularised and final evaluation was presented in a semi-quantitative 
score. 
Fig. 1. PRISMA flowchart.  
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2.4. Data extraction and definition of outcomes 
Features of included and excluded studies were tabularized with 
reason for inclusion or exclusion in tables designed for this study. 
Descriptive data on methods, participants, intervention and control, 
outcome measures, trial/study name, group, centre, ID number, address 
for correspondence, funding, sample size, detailed treatment modality, 
accrual period, length of follow up, patients lost to follow up, subgroup 
analyses were obtained. The following quantitative data were extracted: 
the number of patients with PS ≤ 1 and PS ≥ 2 (and detailed values for 
each 0–4 group if available), the number of responses (CR + PR, SD, PD) 
and grade ≥3 AEs for each PS subgroup, OR with 95 % confidence in-
terval (95 %CI) for ORR, DCR and AE (the odds ratios were calculated 
from the direct numbers when available) as well as HR together with 95 
%CI for OS and PFS. Data for the following subgroups were sought: 
disease stage (IV or other), race, histological type (squamous vs. 
adenocarcinoma), druggable oncogenic mutation status (EGFR, ALK, 
ROS1, BRAF vs. none), age (75 and younger vs. older), treatment line 
(first vs. subsequent), brain metastases (yes vs. no), autoimmune disor-
ders (yes vs. no), immunohistochemical status of PD-L1 (0 % vs. 1–50 % 
vs. >50 %). The potential (partial or complete) overlap between the 
studies was assessed based on the lists of authors and participating 
centres, accrual period, applied treatment, patients’ characteristics and 
outcome measures [16]. In case of complete overlap, only the most 
comprehensive study was included. Studies with potential partial 
overlap were marked as separate subgroups and an additional analysis 
was performed including only the largest study from each subgroup. 
If specific data were not accessible through article (including sup-
plementary material), the corresponding Author was contacted via ac-
ademic e-mail. In case of no response within two weeks, the queries were 
repeated with the time for closure of data accrual within a month from 
the initial e-mail. If meta-analysis was not applicable (e.g. because of the 
lack of data) the results were reported descriptively (tabularized and 
discussed). 
2.5. Data analysis 
Meta-analysis was conducted for differences between PS ≤ 1 vs. PS ≥
2 groups using random effects model on all prespecified outcome mea-
sures (ORR, DFS, OS, PFS, Safety). Total and subtotal odds ratios (OR) or 
hazard ratios (HR) with 95 % CI, prediction intervals (PI) [17,18] and 
overall effect (p-value). The results were presented as forest plots and 
L’Abbé plots [19]. For the assessment of heterogeneity between studies 
I2 values were calculated (between-study variance was assessed ac-
cording to DerSimonian and Laird method [20]). Publication bias was 
assessed with funnel plots and tests for funnel plot asymmetry [21,22], 
and “Trim and Fill” method [23]. R version 4.0.0 [24] and the meta 
package [25] were used for data analysis and visualisation (code 
available upon request and will be publicly available in the companion 
Data in Brief paper). 
2.6. Role of the funding source 
The funder of the study played no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report. All au-
thors had full access to all the data in the study and the corresponding 
author had final responsibility for the decision to submit for publication. 
3. Results 
A total of 4504 publications were retrieved through the literature 
search, and 67 studies with a total of 26,442 patients (individual study 
median: 217, range: 44− 2,302) were included in the final analyses 
(Fig. 1, Table D.01) [6,7,26–90]. Among these, there were 3890 PS ≥ 2 
patients (median: 39, range: 11–241) and 22,552 PS ≤ 1 patients (me-
dian: 170, range: 32− 2,129). ICIs were administered as first line 
treatment in four studies, as the second or further line in thirty-four 
studies, twenty-six studies included both treatment-naïve and 
pre-treated patients, while no data was available for three studies. 
Twelve studies included only specific populations of patients: with 
PD-L1 tumour proportion score ≥50 % (four studies); older age (three 
studies); with oncogenic driver mutations (two studies); with squamous 
cell carcinoma, with concurrent TBC/HBV infection and with African 
American descent or chronic viral infections (one study each). 
3.1. Objective response rate 
Thirty-six studies provided data on objective response rate (n = 9888 
patients; 1937 PS ≥ 2 and 7951 PS ≤ 1); for 33 of these, direct responder 
numbers were also available (Fig. 2). The odds ratio for ORR in PS ≥ 2 vs. 
PS ≤ 1 patients was 0.46 (95 %CI: 0.39− 0.54; PI: 0.39− 0.54) with low 
heterogeneity (I2 = 0 %) (Fig. 3A). The results did not differ significantly 
in the following subgroups of studies: with different lines of treatment 
(Fig. D.01), with different quality according to Newcastle-Ottawa Scale 
(Fig. D.02), with a focus on specific populations (Fig. D.03), with 
different source of data (Fig. D.04) and after exclusion of the studies 
with potential partial overlap of patients (Fig. D.05, OR range: 
0.42− 0.60). The analysis of funnel plot asymmetry identified the po-
tential publication bias (rank correlation test [21] p = 0.003, linear 
regression test [22] p = 0.015; Fig. D.06); however, accounting for the 
potentially missing studies using the “trim and fill” method [23] did not 
affect the pooled result (OR = 0.48, 95 %CI: 0.41− 0.56; Fig. D.07). 
The proportion of responders among the PS ≥ 2 patients showed a 
higher degree of heterogeneity, ranging from 0 % to 42 % (I2 = 59 %) 
with the pooled rate of 15 % (95 %CI: 0.12− 0.19; PI: 0.06− 0.34; 
Fig. D.08). In the subgroup analysis (Fig. 4), patients treated with first- 
line ICI had significantly better response rates (0.32, 95 %CI: 
0.22− 0.44), than patients treated with ICI as a subsequent line (0.11, 95 
%CI: 0.09− 0.14; p < 0.001). 
3.2. Disease-control rate 
Twenty-seven studies provided data on disease control rate (n =
8325 patients; 1473 PS ≥ 2 and 6852 PS ≤ 1), including direct numbers 
of non-progressors (Fig. 2). The odds ratio for DCR in PS ≥ 2 vs. PS ≤ 1 
patients was 0.39 (95 %CI: 0.33− 0.48; PI: 0.20− 0.78) with moderate 
heterogeneity (I2 = 45 %, Fig. 3B). The results did not differ significantly 
in the following subgroups of studies: with different lines of treatment 
(Fig. D.09), with different quality according to Newcastle-Ottawa Scale 
(Fig. D.10), with a focus on specific populations (Fig. D.11), with 
different source of data (Fig. D.12) and after exclusion of the studies 
with potential partial overlap of patients (Fig. D.13, OR range: 
0.36− 0.53). The analysis of funnel plot asymmetry identified no po-
tential publication bias (rank correlation test [21] p = 0.19, linear 
regression test [22] p = 0.54; Fig. D.14) and accounting for the poten-
tially missing studies using the “trim and fill” method [23] did not affect 
the pooled result (OR = 0.41, 95 %CI: 0.33− 0.50; Fig. D.15). 
The proportion of non-progressors among the PS ≥ 2 patients showed 
a higher degree of heterogeneity, ranging from 15 % to 72 % (I2 = 73 %) 
with the pooled rate of 39 % (95 %CI: 0.33− 0.45; PI: 0.17− 0.65; 
Fig. D.16). In the subgroup analysis (Fig. D.17), patients treated with 
first-line ICI had significantly better response rates (0.61, 95 %CI: 
0.49− 0.73) than patients treated with ICI as a subsequent line (0.37, 95 
%CI: 0.29− 0.24; p < 0.001). 
3.3. Progression-free survival 
Thirty-five studies provided data on progression-free survival (n =
12,491 patients; 1843 PS ≥ 2 and 10,648 PS ≤ 1). The hazard ratio for 
PFS in PS ≥ 2 vs. PS ≤ 1 patients was 2.17 (95 %CI: 1.96–2.39; PI: 
1.36–3.44) with considerable heterogeneity (I2 = 63 %, Fig. 5A). The 
results did not differ significantly in the following subgroups of studies: 
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with different lines of treatment (Fig. D.18), with different quality ac-
cording to Newcastle-Ottawa Scale (Fig. D.19), with a focus on specific 
populations (Fig. D.20), with different source of data (Fig. D.21) and 
after exclusion of the studies with potential partial overlap of patients 
(Fig. D.22, HR range: 1.79–2.22). The analysis of funnel plot asymmetry 
identified no potential publication bias (rank correlation test [21] p =
0.250, linear regression test [22] p = 0.320; Fig. D.23) and accounting 
for the potentially missing studies using the “trim and fill” method [23] 
did not affect the pooled result (HR = 2.07, 95 %CI: 1.87–2.30; 
Fig. D.24). 
Fig. 2. L’Abbé plots for Objective Response Rate and Disease Control Rate. The size of each point is scaled according to the weights of random effects model.  
Fig. 3. Forest plots for the Odds Ratio of Overall Response Rate (A) and Disease Control Rate (B).  
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3.4. Overall survival 
Thirty-nine studies provided data on overall survival (n = 17,600 
patients; 2373 PS ≥ 2 and 15,227 PS ≤ 1). The hazard ratio for OS in PS 
≥ 2 vs. PS ≤ 1 patients was 2.76 (95 %CI: 2.43–3.14; PI: 1.38–5.53) with 
marked heterogeneity (I2 = 77 %, Fig. 5B). The results did not differ 
significantly in the following subgroups of studies: with different lines of 
treatment (Fig. D.25), with different quality according to Newcastle- 
Ottawa Scale (Fig. D.26), with a focus on specific populations 
(Fig. D.27), with different source of data (Fig. D.28) and after exclusion 
of the studies with potential partial overlap of patients (Fig. D.29, HR 
range: 2.20–3.11). The analysis of funnel plot asymmetry identified no 
potential publication bias (rank correlation test [21] p = 0.640, linear 
regression test [22] p = 0.090; Fig. D.30) and accounting for the 
potentially missing studies using the “trim and fill” method [23] did not 
affect the pooled result (HR = 2.36, 95 %CI: 2.07–2.70; Fig. D.31). 
3.5. Adverse events 
Twenty-five studies provided data on adverse effects (n = 7302 pa-
tients; 1339 PS ≥ 2 and 5963 PS ≤ 1). The odds ratio for AEs in PS ≥ 2 vs. 
PS ≤ 1 patients was 1.12 (95 %CI: 0.84–1.48; PI: 0.46–2.73) with 
moderate heterogeneity (I2 = 37 %, Fig. 6). The results did not differ 
significantly in the following subgroups of studies: with different lines of 
treatment (Fig. D.32), with different quality according to Newcastle- 
Ottawa Scale (Fig. D.33), with a focus on specific populations 
(Fig. D.34), with different source of data (Fig. D.35) and after exclusion 
of the studies with potential partial overlap of patients (Fig. D.36, OR 
range: 0.63–1.27). The analysis of funnel plot asymmetry identified no 
potential publication bias (rank correlation test [21] p = 0.460, linear 
regression test [22] p = 0.670; Fig. D.37). 
4. Discussion 
The pooled results from 67 studies identified in our systematic re-
view and meta-analysis have demonstrated a significant reduction in 
both ORR and DCR in PS ≥ 2 NSCLC patients treated with ICIs when 
compared with PS ≤ 1 patients. The safety analysis showed that the ratio 
of severe AEs was similar regardless of the PS score. 
The management strategy of NSCLC patients with poor PS remains 
the subject of a debate [91]. The body of prospective evidence 
addressing this unmet need is very limited. The CheckMate 153 and 171 
trials of nivolumab in previously treated patients with NSCLC showed 
favourable safety profile in PS = 2 patients, but the median OS in this 
group was only 4–5 months [6,7]. The TAIL trial provided similar results 
(presented during ESMO 2019) for atezolizumab in pretreated NCSLC 
patients with stage IIIb-IV disease [10]. A median OS for PS = 2 patients 
in this study was merely 3.5 months, considerably shorter than in the 
overall population (11.1 months). The CheckMate 817 trial evaluates 
both nivolumab and ipilimumab in the previously untreated stage IV or 
recurrent NSCLC [92]. The full results have not been published yet, but 
the early data presented at the ESMO Immuno-Oncology Congress 2019 
indicate both fair safety profile and promising OS outcomes in patients 
with co-morbidities or poor PS. Still, the median OS was much shorter in 
this group (i.e. 9.9 months vs. 17.0 months in PS ≤ 1 patients). The 
PePS2 study is the first prospective single arm trial that specifically 
enrolled only PS = 2 patients with NSCLC to be treated with pem-
brolizumab in both first and subsequent line [9]. Similarly to CheckMate 
trials, the treatment was safe in this population and the median OS of 9.8 
months was comparable with the results of CheckMate 817 study. 
Importantly, all aforementioned trials were performed in unselected 
populations with a very low proportion of PS = 2 patients (10–15 % in 
CheckMate and TAIL studies). The authors of PePS2 study suggested a 
greater clinical benefit with higher PD-L1 expression, but due to limited 
Fig. 4. Forest plot for the Objective Response Rate subgroup analysis according to the line of treatment in PS ≥ 2 patients.  
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sample size, a robust conclusion could not be drawn. Currently, there are 
two ongoing phase III RCTs comparing ICIs with chemotherapy, which 
include PS ≥ 2 patients. The eNERGY trial (NCT03351361) evaluates 
first-line nivolumab plus ipilimumab versus carboplatin-based chemo-
therapy, while the IPSOS trial (NCT03191786) compares first-line ate-
zolizumab with single agent chemotherapy by investigator choice 
(vinorelbine or gemcitabine). Nevertheless, results of these trials are not 
expected soon, thus, no new, high quality prospective data to support 
treatment decisions may not be available in the near future. 
Importantly, patients with PS ≥ 2 represent a heterogeneous popu-
lation [93]. A recent study by Facchinetti et al. showed that in advanced 
NSCLC patients with impaired PS and a PD-L1 TPS ≥ 50 % treated with 
first-line pembrolizumab, outcomes were strongly dependent on the 
reason constituting the poor PS [94]. Patients with PS = 2 due to 
comorbidities had a significantly better prognosis compared with pa-
tients whose poor PS was determined by the disease burden. The limited 
inter- and intra-rater reliability of PS assessment adds another layer of 
complexity [95]. Nevertheless, PS remains a strong prognostic factor in 
NSCLC patients treated with ICIs [96]. Still, the key question whether 
poor PS is also predictive of immunotherapy efficacy remains open. This 
is of particular importance in NSCLC management in which the benefit 
from ICIs has been proven in trial populations which were unrepresen-
tative for the average clinical populations (i.e. younger patients with less 
comorbidities). The issue of sorafenib for hepatocellular carcinoma ex-
emplifies the case that if a drug is administered to ‘real-world’ patients 
who mostly do not meet its trial inclusion criteria, the results might be 
significantly poorer than those reported in the trial [97]. Thus, in such 
cases, there is a non-negligible risk of doing more harm than good. In 
fact, a recent study found that in patients with poor PS, the use of ICIs 
near death was more frequent than in PS ≤ 1 patients, and this treatment 
was associated with increased hospitalizations and in-hospital deaths, 
decreased referral to hospice, and shorter duration of hospice stay [98]. 
Our systematic search provided data an unprecedented number of 
NSCLC patients with poor PS treated with ICIs. We applied a random- 
effects model of meta-analysis due to the high number of retrospective 
studies of various designs and research questions. Crucially, we noted a 
twofold decrease of ORR in PS ≥ 2 patients when compared to the PS ≤ 1 
group, with all included studies consistently reporting worse ORR in 
patients with impaired PS (Fig. 2). The subgroup analyses showed that 
the proportion of responses was greater in patients treated with ICIs in 
the first-line setting when compared to the subsequent lines. A higher 
proportion of responders in this setting is probably related to enrolment 
of patients with tumours showing high PD-L1 expression, whereas later 
line-patients are typically treated independently of PD-L1 status. This, 
however, did not translate to a difference in odds ratios between the 
first-line treatment (0.49) and the subsequent lines (0.43). Thus, the 
benefit of early ICI introduction in patients with high PD-L1 TPS seems 
to be independent of the PS. This is supported by the only prospective 
trial evaluating previously untreated NSCLC patients with PS ≤ 2 
(CheckMate 817), which reported the median OS about twofold greater 
than survival reported in other trials which included poor PS patients. 
Furthermore, our analysis indicates that the OR for DCR (also termed 
clinical benefit rate) is even poorer than for ORR (0.38). Similarly to 
ORR analysis, the proportion of responses and disease stabilization was 
greater in patients treated with ICIs in the first-line setting than in 
subsequent lines, but, again, it did not translate to a difference in odds 
Fig. 5. Forest plots for the Hazard Ratio of Progression-free Survival (A) and Overall Survival (B).  
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ratios. Although planned, the subgroup analysis evaluating the response 
regarding treatment line was imbalanced with the vast majority of 
studies reporting subsequent lines of therapy. Hence, these results 
should be viewed with caution and as hypotheses-generating for future 
clinical trials. We have also performed analyses evaluating the prog-
nostic significance of PS status. Similar to other authors we found that 
this variable has a strong prognostic impact regardless of the treatment 
line. However, worse outcomes were noted in subsequent lines for both 
PFS and OS. Importantly, in both PFS and OS, we noted a greater level of 
heterogeneity with I2 exceeding 50 %. The same issue was reported by 
authors of a meta-analysis focused on the prognostic significance of PS 
[96]. The described high heterogeneity within PS ≥ 2 subgroup appears 
to be the most possible explanation. However, the retrospective nature 
of many included studies has to be also taken into account. Many were 
single centre reports with PFS assessed by the investigators (not by an 
independent panel). Availability of other therapy options and opportu-
nity to participate in early phase clinical trials could also have impacted 
the results. Finally, the analysis of severe AEs did not show differences 
between PS ≤ 1 and PS ≥ 2 patients, confirming the results from pro-
spective trials. However, a high level of heterogeneity should be also 
noted. The vast majority of studies reported insignificant differences in 
severe AE rates between the groups, however, studies with a signifi-
cantly lower [7] or higher [32,65] rates of treatment-related toxicity 
were present. This analysis might be biased by toxicity underreporting 
which is well-described in retrospective studies where toxicity is re-
ported by clinicians [99]. 
The first to be named among limitations of this meta-analysis is that 
the majority of included studies were retrospective with no blinded in-
dependent central review of response assessment. However, a recent 
analysis of large number of phase III RCTs in patients with solid tumours 
found no systematic bias between local and central assessments [100]. 
Moreover, we applied the Newcastle-Ottawa Score for Quality Assess-
ment and it accounts for the reported and factual methodology of 
outcome assessment across studies [14,15]. The majority of the included 
studies reported satisfying and robust methodology for outcome 
assessment, which could be partially explained by the fact that treat-
ment with ICIs is still under tight control across economical medical 
systems due to its high cost. On the other hand, adverse events are often 
underreported in retrospective studies, and even in the more rigorously 
controlled setting of clinical trial [101]. This may also be noted in this 
analysis as there were relatively fewer studies reporting safety data. A 
lower amount of heterogeneity observed for ORR and DCR may partially 
result from the fact that some patients did not survive long enough to 
undergo a radiological assessment of response. However, we noted that 
a significant publication bias was present only in ORR analysis. It should 
be emphasized that different studies specified different outcome 
Fig. 6. Forest plot for the Odds Ratio of Adverse Events.  
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measures – for nearly all studies reporting DCR, ORR was also available, 
but not vice versa, as seen in Fig. 3, panels A and B. In result, ORR 
analysis included the smallest studies which often tend to overestimate 
the true effect size (selection bias due to a phenomenon known as the 
"winner’s curse") [102]. Nevertheless, trim and fill analysis showed that 
these deviations did not affect the pooled result. When results of the 
studies were not reported in a format suitable for meta-analysis, we tried 
to contact the study authors and pharmaceutical company sponsors with 
a request for additional data. While none of the pharmaceutical com-
panies have responded to our messages, in contrast, the responses from 
individual investigators were very helpful. We received 22 responses 
which greatly improved the quality of our paper and allowed an increase 
in the study sample size. Finally, the absence of studies with a control 
group consisting of patients treated with cytotoxic agents makes it 
impossible to evaluate whether patients with poor PS should be offered 
chemotherapy instead. Such head-to-head comparisons are of utmost 
importance and we believe that they should be rigorously tested in 
prospective RCTs. This suggestion stands in line with the recent state-
ments calling to broaden the eligibility criteria to make RCTs more 
generalizable [103]. Future clinical trials should include a very detailed 
evaluation of patients’ PS, similar to the PePS2 study, together with the 
assessment of the reason of poor PS determination. Due to the fact that 
the vast majority of industry-funded clinical trials are done solely in PS 
0-1 patients, we suggest that such an initiative may be started by the 
academic community. The example of the recently reported LungART 
trial [104] shows that properly designed academic trials investigating 
the most important clinical endpoints, i.e. OS and QoL, could be practice 
changing. 
While data from RCTs are lacking, the presented herein meta- 
analysed “real-world” and trial data suggest caution with the use of 
ICI in NSCLC patients with PS ≥ 2 or higher. Such patients are, on 
average, twice less likely to achieve CR, PR or even SD when exposed to 
ICIs when compared to a representative PS ≤ 1 population. The prog-
nostic significance of poor PS status was confirmed for both PFS and OS. 
Nonetheless, the safety profile is comparable irrespective of the PS score. 
In our opinion, future studies should primarily investigate whether there 
is an actual benefit of ICIs versus chemotherapy in PS ≥ 2 NSCLC pa-
tients, and focus on identifying tools to allow patient selection for those 
who may benefit more from ICI therapy. 
Funding 
This work was supported by statutory funds of Medical University of 
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